Here is the complete patent application following the provided outline and incorporating the research paper's invention:

# DESCRIPTION  

## BACKGROUND  

The present invention relates generally to the field of viral diagnostics and more specifically to a CRISPR-Cas based system for detecting viral nucleic acids. Infectious diseases caused by viruses and other pathogens continue to pose significant threats to global public health, as demonstrated by recent outbreaks including COVID-19 caused by SARS-CoV-2. Current diagnostic methods for viral infections face several limitations including insufficient sensitivity, reliance on specialized equipment, and inability to distinguish between active and past infections.  

Traditional nucleic acid detection methods such as polymerase chain reaction (PCR), while sensitive, require expensive thermocycling equipment and trained personnel. Recent CRISPR-Cas based detection systems utilizing Cas12 and Cas13 enzymes have shown promise but still suffer from limitations in sensitivity and versatility. There remains an unmet need for a rapid, sensitive, and versatile viral detection system that can be deployed as point-of-care testing without requiring sophisticated laboratory equipment.  

## BRIEF SUMMARY  

The present invention provides a novel viral detection system termed MORIARTY (Multipronged, One-pot, target RNA-Induced, Augmentable, Rapid, Test sYstem) based on Type III-A CRISPR-Cas systems. The system utilizes the unique multicomponent enzymatic activities of the Csm complex including: (1) specific cleavage of viral transcripts by the Csm3 subunit, (2) collateral DNase activity by the HD domain of Csm1, (3) cyclic oligoadenylate (cOA) synthesis by the Csm1 GGDD motif, and (4) cOA-activated collateral RNase by the ancillary enzyme Csm6.  

The MORIARTY system provides several advantages over existing detection methods. First, it offers inherent signal amplification through cOA-mediated activation of Csm6 RNase activity. Second, it provides multipronged detection capabilities through both DNase and RNase reporter systems that can operate under various buffer conditions. Third, the system can detect both RNA and DNA viruses through direct RNA detection or transcription-activated DNA detection. Fourth, the system achieves high sensitivity without requiring expensive equipment, making it suitable for point-of-care applications.  

## DETAILED DESCRIPTION  

The MORIARTY system comprises several key components that work together to provide sensitive and specific detection of viral nucleic acids. The core detection module consists of a Type III-A CRISPR-Csm effector complex programmed with a guide RNA specific to the target viral sequence. The Csm complex is preferably derived from Lactococcus lactis (LlCsm) and includes all Csm subunits (Csm1-Csm6) along with the crRNA. The system further includes the ancillary RNase enzyme Csm6 which is activated by cOA molecules produced by the Csm1 subunit upon target recognition.  

For signal detection, the system utilizes fluorescent reporter molecules including:  
1) A DNA oligonucleotide reporter labeled with a fluorophore-quencher pair (e.g., Alexa594/Iowa Black RQ) that is cleaved by the Csm1 DNase activity  
2) An RNA oligonucleotide reporter labeled with a different fluorophore-quencher pair (e.g., FAM/Iowa Black FQ) that is cleaved by the Csm6 RNase activity  

The system can operate in multiple configurations:  
1) Direct RNA detection mode where target viral RNA activates the Csm complex  
2) Transcription-coupled DNA detection mode where DNA templates are transcribed by T7 RNA polymerase to produce activating RNA  
3) Amplification-coupled mode where viral RNA is first amplified by RT-RPA (reverse transcription-recombinase polymerase amplification)  

Key reaction components include:  
- Buffer system (e.g., 33 mM Tris acetate pH 7.6, 66 mM potassium acetate)  
- Divalent metal ions (Mg2+ for cOA synthesis, Mn2+ for DNase activity)  
- ATP (0.05-1.5 mM depending on configuration)  
- Fluorescent reporters (0.5-2 μM)  
- Csm effector complex (250 nM)  
- Csm6 (1-250 nM)  

The system achieves high sensitivity through several mechanisms:  
1) Signal amplification via cOA-mediated activation of Csm6 RNase  
2) Multiplex targeting of multiple viral sequences  
3) Optimization of metal ion and ATP concentrations  
4) Use of stabilized Csm variants (e.g., Csm3 D30A mutant)  

### EXAMPLES  

Example 1: Amplification-free detection of SARS-CoV-2 RNA  
The MORIARTY system was configured to detect synthetic SARS-CoV-2 Spike (S) gene RNA without amplification. The reaction contained:  
- 250 nM LlCsm_S0_D30A effector complex (targeting S gene nucleotides 22280-22308)  
- 250 nM LlCsm6  
- 2 μM RNA-FAM reporter  
- 10 mM MgCl2  
- 1.5 mM ATP  
- 33 mM Tris acetate pH 7.6  
- 66 mM potassium acetate  

The system detected S gene RNA at concentrations as low as 5 fM with high confidence compared to negative controls.  

Example 2: Multiplexed detection of SARS-CoV-2  
Three LlCsm effector complexes targeting different regions of the S gene (nucleotides 22280-22308, 24702-24730, and 25061-25089) were combined in a single reaction. This multiplex configuration improved detection sensitivity to 2000 copies/μL when testing independently quantified SARS-CoV-2 RNA.  

Example 3: RT-RPA coupled detection  
Viral RNA was first amplified by RT-RPA using S gene-specific primers, then detected by T7-MORIARTY. The reaction contained:  
- 250 nM LlCsm_S0_D30A  
- 250 nM LlCsm6  
- 2 μM DNA-FAM and RNA-FAM reporters  
- 10 mM MgCl2  
- 0.5 mM MnCl2  
- 0.5 mM rNTPs  
- 60 μg/mL T7 RNA polymerase  

This configuration achieved detection sensitivity of 62 copies/μL and correctly identified 7 of 8 qPCR-positive patient samples.  

### Material and Methods  

1. Protein Production:  
The LlCsm effector complex was expressed in E. coli from an all-in-one plasmid encoding all Csm subunits and crRNA. The complex was purified by Ni-NTA affinity chromatography followed by size-exclusion chromatography in 20 mM HEPES pH 7.5, 200 mM NaCl, 5 mM MgCl2, 14 mM 2-mercaptoethanol. LlCsm6 was expressed and purified separately using similar methods.  

2. Guide RNA Design:  
crRNAs were designed to target specific regions of viral genomes (e.g., SARS-CoV-2 S gene) with 29-nucleotide complementarity. The target regions were selected to ensure proper activation of the Csm complex.  

3. Fluorescent Reporters:  
DNA and RNA reporters were synthesized with 5' fluorophores (Alexa594 or FAM) and 3' quenchers (Iowa Black RQ or FQ). The DNA reporter sequence was 5'-Alexa594-ATATATAT-Iowa Black RQ-3'. The RNA reporter sequence was 5'-FAM-UUUUU-Iowa Black FQ-3'.  

4. Reaction Conditions:  
Standard reaction conditions included:  
- 33 mM Tris acetate pH 7.6  
- 66 mM potassium acetate  
- 0.5-2 μM fluorescent reporters  
- 250 nM LlCsm complex  
- 1-250 nM LlCsm6  
- 0-10 mM MgCl2/MnCl2  
- 0-1.5 mM ATP  
- Target nucleic acid (5 fM-500 nM)  
Reactions were performed at 37°C with fluorescence monitored in real-time.  

5. Patient Sample Testing:  
Nasopharyngeal swab samples were extracted using QIAamp viral RNA kits. RNA was tested directly in amplification-free MORIARTY or after RT-RPA amplification in T7-MORIARTY configurations. Results were compared to FDA-approved qRT-PCR assays.  

The MORIARTY system represents a significant advance in viral diagnostics by combining the sensitivity of nucleic acid amplification with the simplicity of CRISPR-based detection in a versatile, multipronged platform suitable for point-of-care applications.